[go: up one dir, main page]

MA27690A1 - Composition pharmaceutique androgene et procede pour le traitement de la depression. - Google Patents

Composition pharmaceutique androgene et procede pour le traitement de la depression.

Info

Publication number
MA27690A1
MA27690A1 MA27858A MA27858A MA27690A1 MA 27690 A1 MA27690 A1 MA 27690A1 MA 27858 A MA27858 A MA 27858A MA 27858 A MA27858 A MA 27858A MA 27690 A1 MA27690 A1 MA 27690A1
Authority
MA
Morocco
Prior art keywords
subject
androgenic
depression
treatment
pharmaceutical composition
Prior art date
Application number
MA27858A
Other languages
English (en)
Inventor
Robert E Dudley
George S Kottayil
Olivier Palatchi
Original Assignee
Unimed Pharmaceuticals Inc
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/098,232 external-priority patent/US20040002482A1/en
Priority claimed from US10/153,468 external-priority patent/US20040092494A9/en
Application filed by Unimed Pharmaceuticals Inc, Besins Int Lab filed Critical Unimed Pharmaceuticals Inc
Publication of MA27690A1 publication Critical patent/MA27690A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés, des kits, des combinaisons et des compositions pour traiter, prévenir ou réduire le risque de développer un trouble dépressif, ou les symptômes associés ou liés à un trouble dépressif chez un sujet en ayant besoin. La présente invention concerne également un procédé pour administrer un stéroïde dans la voie de synthèse de la testostérone, par exemple de la testostérone, à un sujet en ayant besoin. En outre, les procédés, kits, combinaisons et compositions peuvent être utilisés en conjonction avec d'autres agents pharmaceutiques incluant des agents efficaces pour traiter, prévenir ou réduire le risque de développer un trouble dépressif chez un sujet.
MA27858A 2002-03-15 2004-09-14 Composition pharmaceutique androgene et procede pour le traitement de la depression. MA27690A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/098,232 US20040002482A1 (en) 2000-08-30 2002-03-15 Androgen pharmaceutical composition and method for treating depression
US10/153,468 US20040092494A9 (en) 2000-08-30 2002-05-21 Method of increasing testosterone and related steroid concentrations in women

Publications (1)

Publication Number Publication Date
MA27690A1 true MA27690A1 (fr) 2006-01-02

Family

ID=33302446

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27858A MA27690A1 (fr) 2002-03-15 2004-09-14 Composition pharmaceutique androgene et procede pour le traitement de la depression.

Country Status (10)

Country Link
EP (1) EP1511494B1 (fr)
KR (1) KR20050074896A (fr)
CN (1) CN100544725C (fr)
AU (1) AU2003228314C1 (fr)
CA (1) CA2484164C (fr)
HU (1) HU230920B1 (fr)
MA (1) MA27690A1 (fr)
MX (1) MXPA04008988A (fr)
PL (1) PL373593A1 (fr)
WO (1) WO2004091631A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
AU2006254742C1 (en) * 2005-06-03 2011-11-03 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
CA2610708C (fr) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Methode et composition pour l'administration transdermique d'un medicament
BRPI0611134A2 (pt) 2005-06-03 2010-08-17 Acrux Dds Pty Ltd método e composição para liberação transdérmica de fármaco
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
AU2011329782A1 (en) 2010-11-18 2013-06-20 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
CN116098908A (zh) * 2022-09-07 2023-05-12 宁夏医科大学 一种超生理剂量雄激素在改善前列腺癌中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
EP0998289A1 (fr) * 1997-02-07 2000-05-10 TheraTech, Inc. Composition et procede servant a administrer testosterone a des femmes presentant des symptomes de deficience en testosterone
NZ504423A (en) * 1997-11-10 2003-04-29 Cellegy Pharma Inc Composition having enhanced penetration capabilities and irritation reducing systems
US5880117A (en) * 1998-07-13 1999-03-09 Arnold; Patrick Use of 4-androstenediol to increase testosterone levels in humans
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
KR20030048021A (ko) * 2000-08-30 2003-06-18 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법

Also Published As

Publication number Publication date
EP1511494B1 (fr) 2020-08-19
MXPA04008988A (es) 2006-05-25
CN1652793A (zh) 2005-08-10
EP1511494A1 (fr) 2005-03-09
AU2003228314B8 (en) 2008-04-24
HU230920B1 (hu) 2019-03-28
WO2004091631A1 (fr) 2004-10-28
CA2484164C (fr) 2009-12-29
CN100544725C (zh) 2009-09-30
PL373593A1 (en) 2005-09-05
KR20050074896A (ko) 2005-07-19
HUP0600855A3 (en) 2012-09-28
AU2003228314A1 (en) 2004-11-04
HUP0600855A2 (en) 2007-02-28
AU2003228314B2 (en) 2008-04-10
EP1511494A4 (fr) 2010-10-06
AU2003228314C1 (en) 2009-03-26
CA2484164A1 (fr) 2004-10-28

Similar Documents

Publication Publication Date Title
MA26702A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
TN2010000073A1 (fr) Compositon pharmaceutique contenant un derive de benzene substitue par glucopyranosyle
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA27802A1 (fr) Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies.
TNSN07478A1 (fr) Ingredient pharmaceutique actif du cannabinoide pour des formes de dosage ameliorees
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TW200509937A (en) Novel compounds and their use in therapy
MA30720B1 (fr) Analogues de 2-phenoxypyrimidinone
EP1098642A4 (fr) Methodes de traitement d'etats modules par la lactosylceramide
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
BG105302A (en) Means for improving cognition
BR9808606A (pt) Materiais e métodos para tratamento de doenças com ribozimas
MA50675B1 (fr) Inhibiteurs de la creb binding protein (cbp)
ATE531366T1 (de) Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments
WO2002039994A3 (fr) Methodes de traitement et de prevention des calculs urinaires
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif